Navigation Links
Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
Date:12/5/2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Mindray Medical International Limited (NYSE: MR), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Mindray Medical International Limited Research Report

On November 26, 2013, Mindray Medical International Limited (Mindray) announced that it will host its 2013 annual general meeting of record at the Company's Hong Kong office on December 17, 2013 at 11:00 a.m. Beijing/Hong Kong Time (December 16, 2013 at 10:00 p.m. US ET). Mindray reported that the shareholder record date is November 12, 2013. In addition, Mindray informed that its Form 20-F and proxy materials are accessible through the Investor Relations website. The Full Research Report on Mindray Medical International Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8d4d_MR

--

AcelRx Pharmaceuticals, Inc. Research Report

On December 2, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that its Zalviso New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. Richard King, President and CEO of AcelRx commented, "We are extremely pleased with the filing of our NDA for Zalviso, representing achievement of another critical milestone for AcelRx. Zalviso, if approved, will provide hospitalized patients with a non-programmable, non-invasive, patient-controlled treatment option for the management of moderate-to-severe acute pain with a rapid onset of pain relief compared to the commonly used, intravenous patient controlled analgesia systems that typically utilize morphine." The Full Research Report on AcelRx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1454_ACRX

--

Merrimack Pharmaceuticals, Inc. Research Report

On November 26, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced results of two Phase 2 studies evaluating MM-121 in the treatment of women with ER/PR+, HER2 negative breast cancer. Merrimack reported that the MM-121 is a monoclonal antibody designed to target the ErbB3 (HER3) receptor and to interfere with growth factor-mediated resistance to standard-of-care therapies. According to Merrimack, one study was conducted in metastatic breast cancer (mBC) in combination with exemestane, while the second study was conducted in the neoadjuvant setting in combination with paclitaxel followed by doxorubicin and cyclophosphamide. The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8bb0_MACK

--

ZELTIQ Aesthetics, Inc. Research Report

On December 2, 2013, ZELTIQ Aesthetics, Inc. (ZELTIQ) announced that the Company is participating at the upcoming J.P. Morgan SMid Cap Conference at The Westin River North in Chicago on December 11, 2013. According to ZELTIQ, Patrick F. Williams, Senior Vice President and CFO of the Company is scheduled to present at the conference at approximately 8:00 a.m. CT. ZELTIQ also informed that the audio webcast of the Company's presentation and its replay will be available for 90 days at its Investor Relations website. The Full Research Report on ZELTIQ Aesthetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b15b_ZLTQ

--

Clovis Oncology, Inc. Research Report

On December 2, 2013, Clovis Oncology, Inc. (Clovis) announced that certain selling stockholders have commenced an underwritten public offering of 2 million shares of the Company's common stock, which they recently acquired as consideration in connection with Clovis' acquisition of EOS (Ethical Oncology Science) S.p.A. Clovis reported that the net proceeds from the sale will be received by the selling stockholders and not by the Company, and the total number of shares of its outstanding common stock will not change as a result of the offering. Clovis also informed that the selling stockholders intend to grant J.P. Morgan Securities LLC, the sole manager for the offering, a 30-day option to purchase up to an additional 15% of the number of shares sold to cover over-allotments, if any. The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

 


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
2. Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
3. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
4. Eisai Oncology to Present New Research on Eribulin and NEPA at 36th Annual San Antonio Breast Cancer Symposium
5. RheumatologyNetwork Presents RA Findings from ACR Annual Meeting
6. Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto
7. Agility-PSR Wins "Best Contract Research Organization" in the 2013 ROAR Awards at the 4th Annual World Orphan Drug Conference in Geneva
8. Isis Pharmaceuticals to Present at the Oppenheimer 24th Annual Healthcare Conference
9. MultiVu Video Feed: New Medical Studies From The 2013 RSNA Annual Meeting
10. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
11. Nora Therapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan 23, 2017 NeuroVive Pharmaceutical AB ... signed a preclinical collaboration agreement with the Children,s Hospital of ... Falk , M.D., a US key opinion leader in the ... ... evaluate compounds from NeuroVive,s research program, NVP015, in certain experimental ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 23, 2017 , ... “Life Under Blankets”: an entrancing story about one ... Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her bachelor’s ... went on to pursue a master’s degree in education in the field of curriculum ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
(Date:1/22/2017)... FL (PRWEB) , ... January 22, 2017 , ... Zifam ... customers across the world, recently met with big-name retail buyers at the January ECRM ... evidence of efficacy and uses the utmost safety standards in all of its creations ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
Breaking Medicine News(10 mins):